pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Vyvgart
drug · protein
save

efgartigimod alfa

pre_registrationupdated 6mo ago
by $ARGX ARGENX SE🔗 ChEMBL
community read0 votes

🐶 often sniffed alongside

top 3
  • tagApproval52 co-mentions · 13 sources
  • drugicosapent ethyl26 co-mentions · 13 sources
  • drug(efgartigimod alfa + hyaluronidase (human recombinant))16 co-mentions · 8 sources

Protein drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 14 investigational indications.

targets

IgG receptor FcRn large subunit p51

all catalysts(0)

nothing on the calendar yet

Trials studying efgartigimod alfa

  • phase2Efgartigimod for the Treatment of Acute Optic Neuritisrecruitingn=20
  • phase2Evaluating Efgartigimod in Patients With Guillain-Barré Syndromewithdrawn

News(10)

  • Deaths, failed trials and other recent setbacks in the autoimmune space
    Novartis, Bristol Myers Squibb, argenx and more have recently been hit with challenges as they attempt to advance assets targeting autoimmune diseases, with some programs being axed entirely while…
    biospace · 1d ago
  • Argenx is spending billions to push beyond Vyvgart
    Six months into her term as CEO of rare disease drugmaker argenx, Karen Massey has overseen two acquisitions worth a combined potential of about $3.4 billion as the company seeks to build a broader…
    endpoints · 3d ago
  • Argenx to buy peptide platform in potentially billion-dollar deal
    For $550 million up front, Argenx will take control of Unnatural Products’ “macrocyclic peptide” technology and direct it to develop oral, durable medicines for serious immune-mediated diseases.
    biopharma_dive · 7d ago
  • Argenx inks $1.15B Unnatural Products buyout to expand in oral peptides
    Argenx has struck a deal to acquire Unnatural Products for $550 million upfront, snapping up the Merck & Co.- and Novartis-partnered biotech to add oral peptide capabilities.
    fiercebiotech · 8d ago
  • STAT+: Pharmalittle: We’re reading about a setback for Argenx, Lilly suits over copycat versions of an obesity drug, and more
    The FDA flagged a potential safety signal after four patient deaths in a trial testing a schizophrenia drug, Argenx faces an unusual setback, and more pharma news.
    stat · 1mo ago
  • Argenx falls as Sjögren’s setback offsets celiac drug progress
    A monitoring board’s recommendation to stop the study for futility took Wall Street by surprise, removing one more ‘blockbuster expansion opportunity’ for Vyvgart.
    biopharma_dive · 1mo ago
  • Argenx shutters Sjogren's study, losing blockbuster expansion opportunity for Vyvgart
    Argenx shares have fallen more than 13% after the surprise futility finding, which overshadowed a mid-stage celiac disease win for a separate asset acquired in the company’s $2.2 billion Forte Bios…
    biospace · 1mo ago
  • STAT+: Argenx sees unusual setback with failure of late-stage study of drug for autoimmune disease
    Argenx said its blockbuster drug Vyvgart didn’t outperform placebo in a Phase 3 trial of patients with Sjögren's disease, a chronic autoimmune disorder.
    stat · 1mo ago
  • Argenx digests phase 2 celiac win for $2.2B drug, preps pivotal run
    A phase 2 celiac disease trial of argenx’s FB102 has hit its primary endpoint, delivering a boost to a drug candidate that the biotech acquired in its $2.2 billion takeover of Forte Biosciences.
    fiercebiotech · 1mo ago
  • Big Pharma-backed Nuvig halts development of lead fusion protein in rare autoimmune disease
    Big Pharma-backed Nuvig Therapeutics has halted one of the two trials for its sole clinical asset after determining the program wouldn’t be able to advance quickly enough.
    fiercebiotech · 1mo ago
view all news mentions →
brand
Vyvgart
trade names
Efgartigimod alfa component of vyvgart hytrulo, Vyvgart
generic
efgartigimod alfa
MOA
IgG receptor FcRn large subunit p51 antagonist
indication
Myasthenia Gravis
phase
pre_registration
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 18m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?